Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases, Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Rajagopalan, S. Misialek, J. X. Huang, L. Hooi, H. Ramesha, J. Nicholas, J. Ramphal, K. Emayan, L. Pan, S. Yap, L. Huang, S. Seiwert, B. Buckman (Brisbane, United States Of America). Biochemical and functional characterization of lysyl oxidase like 2 (LOXL2) inhibitors. Eur Respir J 2014; 44: Suppl. 58, 1518

Member's Comments

No comment yet.

Related content which might interest you: Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Erythropoietin (EPO) inhibits the immunohistochemical expression of lysyl oxidase (LOX) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Lipoxin (LXA4) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Type II transmembrane serine protease matriptase is a mediator of pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 AAV-Tgfb1 vs. bleomycin: Analysis of gene expression profiles in two models of pulmonary fibrosis Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Molecular mechanisms of pirfenidone activity in human lung fibroblasts Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014 Altered protein homeostasis in pulmonary fibrosis indicates a role for proteasomal activator 200 Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Mitochondrial tRNA gene mutations in patients with idiopathic pulmonary fibrosis (IPF) and sarcoidosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Loss of CARM1 prolongs bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Metformin inhibits TGF-b-induced myofibroblast differentiation through AMPK activation Source: International Congress 2014 – Cell biology 2014 Year: 2014